These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 19969465

  • 1. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS, Tanaka Y, Nabeyama W, Hatori M, Nakamura H.
    Bioorg Med Chem; 2010 Jan 15; 18(2):870-9. PubMed ID: 19969465
    [Abstract] [Full Text] [Related]

  • 2. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
    Ban HS, Usui T, Nabeyama W, Morita H, Fukuzawa K, Nakamura H.
    Org Biomol Chem; 2009 Nov 07; 7(21):4415-27. PubMed ID: 19830290
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT, Yuan TT, Liu HH, Chen SF, Wu YT.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6373-7. PubMed ID: 17889528
    [Abstract] [Full Text] [Related]

  • 4. Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase.
    Ban HS, Onagi S, Uno M, Nabeyama W, Nakamura H.
    ChemMedChem; 2008 Jul 15; 3(7):1094-103. PubMed ID: 18465761
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD, Fang F, Li JR, Du QR, Sun J, Gong HB, Zhu HL.
    Bioorg Med Chem Lett; 2012 Sep 15; 22(18):5870-5. PubMed ID: 22901387
    [Abstract] [Full Text] [Related]

  • 7. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
    Rao GW, Xu GJ, Wang J, Jiang XL, Li HB.
    ChemMedChem; 2013 Jun 15; 8(6):928-33. PubMed ID: 23640754
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
    El Ella DA, Saleh KA, Hassan M, Hamdy N, El-Araby ME, Abouzid KA.
    Arzneimittelforschung; 2012 Aug 15; 62(8):360-6. PubMed ID: 22723174
    [Abstract] [Full Text] [Related]

  • 9. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM, Serrya RA, Kafafy AH, Ahmed M, Wang F, Abouzid KA.
    J Enzyme Inhib Med Chem; 2014 Apr 15; 29(2):215-22. PubMed ID: 23402383
    [Abstract] [Full Text] [Related]

  • 10. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects.
    Antonello A, Tarozzi A, Morroni F, Cavalli A, Rosini M, Hrelia P, Bolognesi ML, Melchiorre C.
    J Med Chem; 2006 Nov 16; 49(23):6642-5. PubMed ID: 17154492
    [Abstract] [Full Text] [Related]

  • 11. Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
    Carmi C, Cavazzoni A, Vezzosi S, Bordi F, Vacondio F, Silva C, Rivara S, Lodola A, Alfieri RR, La Monica S, Galetti M, Ardizzoni A, Petronini PG, Mor M.
    J Med Chem; 2010 Mar 11; 53(5):2038-50. PubMed ID: 20151670
    [Abstract] [Full Text] [Related]

  • 12. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.
    Li RD, Zhang X, Li QY, Ge ZM, Li RT.
    Bioorg Med Chem Lett; 2011 Jun 15; 21(12):3637-40. PubMed ID: 21570843
    [Abstract] [Full Text] [Related]

  • 13. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
    Garofalo A, Goossens L, Lemoine A, Farce A, Arlot Y, Depreux P.
    J Enzyme Inhib Med Chem; 2010 Apr 15; 25(2):158-71. PubMed ID: 20222760
    [Abstract] [Full Text] [Related]

  • 14. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
    Xu YY, Li SN, Yu GJ, Hu QH, Li HQ.
    Bioorg Med Chem; 2013 Oct 01; 21(19):6084-91. PubMed ID: 23962660
    [Abstract] [Full Text] [Related]

  • 15. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
    Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Johnson PD, Kettle JG, Klinowska T, Leach AG, Morgentin R, Pass M, Ogilvie DJ, Olivier A, Warin N, Williams EJ.
    Bioorg Med Chem Lett; 2006 Mar 15; 16(6):1633-7. PubMed ID: 16380259
    [Abstract] [Full Text] [Related]

  • 16. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Lippa B, Kauffman GS, Arcari J, Kwan T, Chen J, Hungerford W, Bhattacharya S, Zhao X, Williams C, Xiao J, Pustilnik L, Su C, Moyer JD, Ma L, Campbell M, Steyn S.
    Bioorg Med Chem Lett; 2007 Jun 01; 17(11):3081-6. PubMed ID: 17398092
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
    Zheng QZ, Zhang F, Cheng K, Yang Y, Chen Y, Qian Y, Zhang HJ, Li HQ, Zhou CF, An SQ, Jiao QC, Zhu HL.
    Bioorg Med Chem; 2010 Jan 15; 18(2):880-6. PubMed ID: 20005116
    [Abstract] [Full Text] [Related]

  • 18. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
    Liu F, Tang B, Liu H, Li L, Liu G, Cheng Y, Xu Y, Chen W, Huang Y.
    Anticancer Agents Med Chem; 2016 Jan 15; 16(12):1652-1664. PubMed ID: 27039919
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Lin R, Johnson SG, Connolly PJ, Wetter SK, Binnun E, Hughes TV, Murray WV, Pandey NB, Moreno-Mazza SJ, Adams M, Fuentes-Pesquera AR, Middleton SA.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2333-7. PubMed ID: 19286381
    [Abstract] [Full Text] [Related]

  • 20. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S, Narla RK, Zheng Y, Liu XP, Jun X, Mao C, Sudbeck EA, Uckun FM.
    Anticancer Drug Des; 1999 Oct 15; 14(5):403-10. PubMed ID: 10766295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.